Global Angina Pectoris Drugs Market Size By Type (Beta Blockers, Calcium Antagonists), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Angina Pectoris Drugs Market was valued at USD 9.2 billion in 2023 and is projected to reach USD 14.6 billion by 2031, expanding at a CAGR of 6.1% during the forecast period from 2023 to 2031. This growth is primarily driven by the rising prevalence of cardiovascular diseases, aging population, lifestyle-related risk factors, and growing awareness of heart health. Angina pectoris drugs play a crucial role in relieving chest pain, improving blood flow, and preventing heart attacks, making them essential in managing coronary artery disease.

Drivers:

1. Rising Cardiovascular Disease Prevalence:

Globally, coronary artery disease is the leading cause of morbidity and mortality. The increasing incidence of angina among patients with ischemic heart conditions fuels demand for long-term therapeutic management.

2. Aging Population:

With the global population over 65 years expanding rapidly, the susceptibility to heart-related disorders such as angina is rising. This demographic trend is boosting the need for chronic treatment options.

3. Lifestyle-Associated Risk Factors:

Poor diet, lack of physical activity, smoking, and rising obesity and diabetes cases contribute significantly to the growing incidence of angina, thereby increasing demand for therapeutic drugs.

Restraints:

1. Patent Expiries and Generic Competition:

The expiration of patents for several branded angina drugs has led to a surge in generic alternatives, affecting revenue generation for key pharmaceutical companies.

2. Adverse Drug Reactions and Contraindications:

Drugs used to treat angina, including nitrates and beta-blockers, can cause side effects such as hypotension, dizziness, or bradycardia, potentially limiting their use in sensitive populations.

Opportunity:

1. Innovation in Drug Delivery and Combination Therapies:

The development of extended-release formulations and fixed-dose combinations offers enhanced compliance and efficacy, presenting lucrative opportunities for pharmaceutical innovators.

2. Emerging Markets and Healthcare Infrastructure Improvements:

Rising healthcare investments in countries like India, Brazil, and China are expanding access to cardiac care, creating new demand for angina pectoris therapies.

Market by System Type Insights:

Based on drug class, Beta-Blockers held the largest market share in 2023, given their proven efficacy in reducing myocardial oxygen demand and improving survival post-cardiac events. However, the Calcium Channel Blockers segment is anticipated to witness the fastest growth, attributed to their increasing use as first-line therapy and favorable safety profile in elderly patients and those with respiratory comorbidities.

Market by End-use Insights:

By end-use, Hospitals dominated the market in 2023, driven by the high volume of angina patients requiring emergency care and diagnostic evaluation. Meanwhile, the Retail Pharmacies segment is projected to grow substantially due to increasing outpatient prescriptions and improved drug accessibility through expanding pharmacy chains.

Market by Regional Insights:

North America accounted for the largest share in 2023 due to high awareness levels, robust reimbursement systems, and advanced healthcare infrastructure. However, Asia-Pacific is forecast to register the highest CAGR through 2031, owing to a large patient pool, increasing healthcare expenditure, and growing government initiatives to manage heart diseases.

Competitive Scenario:

Key players in the Global Angina Pectoris Drugs Market include Pfizer Inc., Novartis AG, Merck & Co., AstraZeneca PLC, Bayer AG, Gilead Sciences, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, and Abbott Laboratories. These companies are actively engaged in expanding their cardiovascular drug portfolios through product launches, strategic collaborations, and R&D in novel formulations.

Scope of Work – Global Angina Pectoris Drugs Market

Key Market Developments:

2023: Novartis AG introduced a new extended-release calcium channel blocker with improved dosing convenience.

2024: Pfizer Inc. partnered with a digital health startup to develop AI-assisted compliance tools for chronic angina therapy.

2025: AstraZeneca received regulatory approval for a new fixed-dose combination therapy targeting stable angina symptoms.

FAQs:

1) What is the current market size of the Global Angina Pectoris Drugs Market?

The Global Angina Pectoris Drugs Market was valued at USD 9.2 billion in 2023.

2) What is the major growth driver of the Global Angina Pectoris Drugs Market?

The major growth driver is the increasing prevalence of cardiovascular diseases worldwide.

3) Which is the largest region during the forecast period in the Global Angina Pectoris Drugs Market?

North America held the largest market share in 2023, but Asia-Pacific is projected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Angina Pectoris Drugs Market?

The Beta-Blockers segment accounted for the largest share by drug class in 2023.

5) Who are the key market players in the Global Angina Pectoris Drugs Market?

Key players include Pfizer Inc., Novartis AG, Merck & Co., AstraZeneca PLC, and Bayer AG.